IMCR (Immunocore Holdings) Debt-to-Equity : 1.15 (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Immunocore Holdings Debt-to-Equity?

Immunocore Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $1.7 Mil. Immunocore Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $432.3 Mil. Immunocore Holdings's Total Stockholders Equity for the quarter that ended in Mar. 2025 was $378.5 Mil. Immunocore Holdings's debt to equity for the quarter that ended in Mar. 2025 was 1.15.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Immunocore Holdings's Debt-to-Equity or its related term are showing as below:

IMCR' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.23 Med: 0.37 Max: 4.02
Current: 1.15

During the past 7 years, the highest Debt-to-Equity Ratio of Immunocore Holdings was 4.02. The lowest was 0.23. And the median was 0.37.

IMCR's Debt-to-Equity is ranked worse than
88.6% of 1026 companies
in the Biotechnology industry
Industry Median: 0.14 vs IMCR: 1.15

Immunocore Holdings Debt-to-Equity Historical Data

The historical data trend for Immunocore Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunocore Holdings Debt-to-Equity Chart

Immunocore Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

1.15

0.37

0.24

0.23

1.20

Immunocore Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Debt-to-Equity	Get a 7-Day Free Trial															1.32	1.32	1.27	1.20	1.15

Competitive Comparison of Immunocore Holdings's Debt-to-Equity

For the Biotechnology subindustry, Immunocore Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunocore Holdings's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunocore Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Immunocore Holdings's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Immunocore Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Immunocore Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.547	+	431.175)	/	360.716
	=	1.20

Immunocore Holdings's Debt to Equity Ratio for the quarter that ended in Mar. 2025 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.717	+	432.278)	/	378.479
	=	1.15

Immunocore Holdings (NAS:IMCR) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Immunocore Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Immunocore Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunocore Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunocore Holdings PLC (NAS:IMCR) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

6YG:Germany

Address

92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY

Website

https://www.immunocore.com

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.